Ahmed Mamdouh Taha Mostafa1, Muhammed Ershad2, Maricel Dela Cruz2, Rita G McKeever2, David Vearrier2, Michael I Greenberg2. 1. Division of Medical Toxicology, Department of Emergency Medicine, Drexel University College of Medicine, 245 N. 15th St., Mail Stop #1011, Philadelphia, PA, 19102, USA. amt.mostafa@gmail.com. 2. Division of Medical Toxicology, Department of Emergency Medicine, Drexel University College of Medicine, 245 N. 15th St., Mail Stop #1011, Philadelphia, PA, 19102, USA.
Abstract
INTRODUCTION: Gadolinium-based contrast agents (GBCA) are frequently used for MRI contrast studies. We report a case of pulmonary aspiration secondary to inadvertent GBCA injection. CASE REPORT: A 12-year-old female with a past medical history significant for mitochondrial disorder, bronchial asthma, autism, recurrent urinary tract infection, epilepsy, developmental delay, dysautonomia, and thrombocytopenia was scheduled for a contrast-enhanced MRI study using gadoterate meglumine for urinary incontinence. The patient was sedated and intubated in preparation for the study, during which 10 mL of gadoterate meglumine was inadvertently injected into the endotracheal tube cuff pilot line instead of intravenously. The patient remained intubated and was admitted to the intensive care unit with continuous monitoring for signs of pulmonary injury or gadolinium toxicity. She was successfully extubated approximately 24 hours later without complication. DISCUSSION: A variety of adverse effects attributable to parenteral GBCA exposure have been reported ranging from mild irritation to life-threatening anaphylaxis. Gadolinium deposition and storage have been implicated in a number of those adverse effects and multiple treatments modalities have been suggested, but no scientifically guided management exists. CONCLUSION: This case of pulmonary aspiration secondary to inadvertent GBCA injection in a pediatric patient demonstrated no acute side effects or complications within the first 24 hours. With the wide range of adverse effects attributed to gadolinium use in the medical literature, it is difficult to predict potential future adverse effects.
INTRODUCTION:Gadolinium-based contrast agents (GBCA) are frequently used for MRI contrast studies. We report a case of pulmonary aspiration secondary to inadvertent GBCA injection. CASE REPORT: A 12-year-old female with a past medical history significant for mitochondrial disorder, bronchial asthma, autism, recurrent urinary tract infection, epilepsy, developmental delay, dysautonomia, and thrombocytopenia was scheduled for a contrast-enhanced MRI study using gadoterate meglumine for urinary incontinence. The patient was sedated and intubated in preparation for the study, during which 10 mL of gadoterate meglumine was inadvertently injected into the endotracheal tube cuff pilot line instead of intravenously. The patient remained intubated and was admitted to the intensive care unit with continuous monitoring for signs of pulmonary injury or gadoliniumtoxicity. She was successfully extubated approximately 24 hours later without complication. DISCUSSION: A variety of adverse effects attributable to parenteral GBCA exposure have been reported ranging from mild irritation to life-threatening anaphylaxis. Gadolinium deposition and storage have been implicated in a number of those adverse effects and multiple treatments modalities have been suggested, but no scientifically guided management exists. CONCLUSION: This case of pulmonary aspiration secondary to inadvertent GBCA injection in a pediatric patient demonstrated no acute side effects or complications within the first 24 hours. With the wide range of adverse effects attributed to gadolinium use in the medical literature, it is difficult to predict potential future adverse effects.
Authors: Joana Ramalho; Miguel Ramalho; Michael Jay; Lauren M Burke; Richard C Semelka Journal: Magn Reson Imaging Date: 2016-09-28 Impact factor: 2.546
Authors: Richard C Semelka; Clayton W Commander; Michael Jay; Lauren M B Burke; Miguel Ramalho Journal: Invest Radiol Date: 2016-10 Impact factor: 6.016